canada clinical guidance

Shingles (herpes zoster)

A Canadian clinical summary of shingles (herpes zoster), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Herpes zoster (shingles) vaccine: Canadian Immunization Guide. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:NACI zoster

Source-attributed clinical priorities

  • Recognize a unilateral dermatomal vesicular eruption and consider disseminated, ophthalmic, otic and neurologic involvement.
  • Start antiviral treatment promptly for source-defined higher-risk presentations, adjusting for kidney function and interactions.
  • Use current NACI guidance for prevention; vaccine eligibility and public funding differ by province and territory.
  • Document rash onset because antiviral benefit is greatest when treatment starts promptly in eligible patients.
sources for this section:NACI zoster

Practical assessment and management workflow

1
Confirm unilateral dermatomal vesicles and assess eye, ear, motor, disseminated and immunocompromised involvement.
2
Provide analgesia and select antiviral therapy by timing, severity, age, immune status and renal function.
3
Advise lesion coverage and avoidance of susceptible pregnant or immunocompromised contacts until crusted.
4
Review persistent pain and function and distinguish postherpetic neuralgia from ongoing infection.
sources for this section:NACI zoster

Safety, red flags and urgent escalation

  • Eye pain, visual symptoms or lesions on the nose require urgent ophthalmic assessment.
  • Disseminated rash, encephalopathy, motor weakness or severe immunosuppression needs urgent specialist care.
  • Adjust antiviral dose for kidney function and avoid assuming vaccination treats the current episode.
sources for this section:NACI zoster

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:NACI zoster

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:NACI zoster

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. National Advisory Committee on Immunization and Public Health Agency of CanadaHerpes zoster (shingles) vaccine: Canadian Immunization Guideaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.